Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: Two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry

Rheumatology International

Volumn 33, Issue 11, 2013, Pages 2885-2888

  Perdan Pirkmajer, Katja ^a   Hočevar, Alojzija ^a   Rotar, Žiga ^a   Žibert, Janez ^b   Marolt, Vera Ferlan ^c   Gučev, Filip ^a   Tomšič, Matija ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF PRIMORSKA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Liver injury; Rheumatoid arthritis; TNF alpha inhibitors

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER INJURY; LIVER NECROSIS; LOW DRUG DOSE; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SLOVENIA; STEATOSIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; METHYLPREDNISOLONE; REGISTRIES; SLOVENIA; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886728621     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2524-z     Document Type: Article

References (17)

1. Hartmann U, Schmitt S, Reuss-Borst M (2008) Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report. Z Rheumatol 67:440-444
2. Saleem G, Li SC, MacPherson BR, Cooper SM (2001) Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et al. Arthritis Rheum 44:1966-1968
3. Menghini VV, Arora AS (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84-86
4. Wolfe F, Michaud K, Gilmer K (2004) No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis. Ann Rheum Dis 63:199
5. Ierardi E, Della Valle N, Nacchiero MC, De Francesco V, Stoppino G, Panella C (2006) Infliximab single administration followed by acute liver injury. Inflamm Bowel Dis 12:1089-1091
6. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26:578-581
7. Moum B, Konopski Z, Tufteland KF, Jahnsen J (2007) Occurrence of hepatotoxicity and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 13:1584-1586
8. Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD (2008) Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 35:349-351
9. Thiéfin G, Morelet A, Heurgué A, Heurgué A, Diebold MD, Eschard JP (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737-739
10. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA (2010) BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188-193
11. Massarotti M, Marasini B (2009) Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22:547-549
12. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O (2010) Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 44:20-22
13. Shaw JP, Hopfensperger MJ, Ganey PE, Roth RA (2007) Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Tox Sci 100:259-266
14. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al. (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69:1612-1617
15. Murdaca G, Colombo BM, Puppo F (2009) Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 22:557-565
16. Cravo M, Silva R, Serrano M (2010) Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. BioDrugs 24(Suppl 1):25-27
17. Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A (2011) Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 49:38-40